Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27646033
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 J+Transl+Med
2016 ; 14
(ä): 269
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Repurposing of approved cardiovascular drugs
#MMPMID27646033
Ishida J
; Konishi M
; Ebner N
; Springer J
J Transl Med
2016[Sep]; 14
(ä): 269
PMID27646033
show ga
Research and development of new drugs requires both long time and high costs,
whereas safety and tolerability profiles make the success rate of approval very
low. Drug repurposing, applying known drugs and compounds to new indications, has
been noted recently as a cost-effective and time-unconsuming way in developing
new drugs, because they have already been proven safe in humans. In this review,
we discuss drug repurposing of approved cardiovascular drugs, such as aspirin,
beta-blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor
blockers, cardiac glycosides and statins. Regarding anti-tumor activities of
these agents, a number of experimental studies have demonstrated promising
pleiotropic properties, whereas all clinical trials have not shown expected
results. In pathological conditions other than cancer, repurposing of
cardiovascular drugs is also expanding. Numerous experimental studies have
reported possibilities of drug repurposing in this field and some of them have
been tried for new indications ('bench to bedside'), while unexpected results of
clinical studies have given hints for drug repurposing and some unknown
mechanisms of action have been demonstrated by experimental studies ('bedside to
bench'). The future perspective of experimental and clinical studies using
cardiovascular drugs are also discussed.
free
free
free
